FDA Begins Device User Fee Collection; Appropriations Still In Doubt
This article was originally published in The Silver Sheet
MEDICAL DEVICE USER FEE PERFORMANCE GOALS may not be met if promised increases in appropriations for premarket activities are not provided, FDA officials warn. Nevertheless, the Center for Devices and Radiological Health is committed to making progress on its performance goals with available funds and plans to hire about 40 device review staffers over the next two years. CDRH is focusing on educating manufacturers on how to follow new user fee payment procedures to avoid review delays. New guidance for firms eligible for small business discounts is due out this summer
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.